Recent Company News

• 01:03 AM ET Jun 30, 2025
  

  Addex Therapeutics leads CHF2M investment in Stalicla (CHF 0.06, 0.00)

• 01:02 AM ET Jun 19, 2025
  

  Addex Therapeutics reports Q1 net loss (CHF1.5M) vs year-ago (CHF3.1M) (CHF 0.06, 0.00)

• 04:10 AM ET Apr 25, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:05 AM ET Jun 06, 2025
  

  Addex Therapeutics GABAB Pam candidate demonstrates robust anti-tussive activity in multiple chronic cough preclinical models (CHF 0.06, 0.00)

• 01:07 AM ET Jun 05, 2025
  

  Addex to present positive GABAB PAM chronic cough data at the 10th American Cough Conference (CHF 0.06, 0.00)

• 01:05 AM ET May 12, 2025
  

  Addex partner Indivior advances GABAB positive Allosteric modulator program successfully through ind enabling studies (CHF 0.06, 0.00)

• 01:30 AM ET Apr 30, 2025
  

  Addex Therapeutics enters option- and collaboration agreement with Sinntaxis AB for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor subtype 5 inhibitors for the treatment of brain injury recovery